Caricamento...
Clostridioides difficile-induced diarrhoea following dasatinib therapy
Dasatinib, an oral tyrosine kinase inhibitor, is approved for therapy of chronic myeloid leukaemia (CML). Common adverse effects of this therapy include myelosuppression, fluid retention and diarrhoea. However, Clostridioides difficile infections (CDIs) in the context of dasatinib therapy, without a...
Salvato in:
| Pubblicato in: | BMJ Case Rep |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMJ Publishing Group
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7813327/ https://ncbi.nlm.nih.gov/pubmed/33462050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-239394 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|